*	OR T1 T2
R1	Subsumes Arg1:T3 Arg2:T4	
R2	Has_qualifier Arg1:T3 Arg2:T5	
*	OR T10 T11
*	OR T8 T9
R3	AND Arg1:T10 Arg2:T8	
R4	Has_qualifier Arg1:T16 Arg2:T15	
R5	Has_qualifier Arg1:T17 Arg2:T18	
R6	Has_multiplier Arg1:T16 Arg2:T17	
R7	Has_index Arg1:T19 Arg2:T20	
R8	Has_temporal Arg1:T16 Arg2:T19	
R9	Subsumes Arg1:T23 Arg2:T24	
R10	Has_qualifier Arg1:T22 Arg2:T21	
R11	Has_multiplier Arg1:T22 Arg2:T23	
R12	Has_index Arg1:T29 Arg2:T30	
R13	Has_qualifier Arg1:T27 Arg2:T28	
R14	Has_multiplier Arg1:T26 Arg2:T27	
R15	Has_temporal Arg1:T26 Arg2:T29	
R16	Has_qualifier Arg1:T26 Arg2:T25	
R17	Has_qualifier Arg1:T32 Arg2:T31	
R18	Has_multiplier Arg1:T32 Arg2:T37	
R19	Has_multiplier Arg1:T32 Arg2:T33	
R20	Subsumes Arg1:T33 Arg2:T34	
R21	Has_temporal Arg1:T32 Arg2:T35	
R22	Has_index Arg1:T35 Arg2:T36	
R23	Has_negation Arg1:T39 Arg2:T38	
R24	Has_multiplier Arg1:T32 Arg2:T39	
T1	Person 0 4	Male
T2	Person 8 14	female
T3	Drug 33 40	IgPro20
T4	Drug 42 50	Hizentra
T5	Qualifier 18 29	stable dose
T6	Pregnancy_considerations 62 269	Women of childbearing potential must be using and agree to continue using medically approved contraception (which must be discussed with the study doctor) and must have a negative pregnancy test at screening
T7	Condition 286 289	PID
T8	Condition 315 347	common variable immunodeficiency
T9	Condition 351 378	X-linked agammaglobulinemia
T10	Measurement 398 438	Pan American Group for Immune Deficiency
T11	Measurement 447 486	European Society of Immune Deficiencies
T12	Non-query-able 439 442	and
T15	Qualifier 551 574	pump-assisted infusions
T16	Drug 578 585	IgPro20
T17	Multiplier 603 642	flow rate of 25 mL/h per injection site
T18	Qualifier 593 602	tolerated
T19	Temporal 643 678	for at least 1 month prior to Day 1
T20	Reference_point 673 678	Day 1
T21	Qualifier 687 693	weekly
T22	Drug 694 701	IgPro20
T23	Multiplier 710 717	= 50 mL
T24	Multiplier 719 725	= 10 g
T25	Qualifier 745 768	pump-assisted infusions
T26	Drug 772 779	IgPro20
T27	Multiplier 793 824	volumes of 25 mL/injection site
T28	Qualifier 783 792	tolerated
T29	Temporal 825 860	for at least 1 month prior to Day 1
T30	Reference_point 855 860	Day 1
T31	Qualifier 879 887	frequent
T32	Drug 922 929	IgPro20
T33	Multiplier 1012 1030;947 984	per injection site flow rate of approximately 0.5 mL/min
T34	Multiplier 1000 1010	25-30 mL/h
T35	Temporal 1031 1066	for at least 1 month prior to Day 1
T36	Reference_point 1061 1066	Day 1
T37	Multiplier 889 907	2-7 times per week
T38	Negation 1112 1115	not
T39	Multiplier 1116 1129	exceed 25 mL.
